

# E - Index

## In this guide

### [In this guide](#)

1. [A - Index](#)
2. [B - Index](#)
3. [C - Index](#)
4. [D - Index](#)
5. [E - Index](#)
6. [F - Index](#)
7. [G - Index](#)
8. [H - Index](#)
9. [I - Index](#)
10. [J - Index](#)
11. [K - Index](#)
12. [L - Index](#)
13. [M - Index](#)
14. [N - Index](#)
15. [O - Index](#)
16. [P - Index](#)
17. [Q - Index](#)
18. [R - Index](#)
19. [S - Index](#)
20. [T - Index](#)
21. [U - Index](#)
22. [V - Index](#)
23. [W - Index](#)
24. [X - Index](#)
25. [Y - Index](#)
26. [Z - Index](#)

**Subject:****ECETOC****Year Page**

Monograph on Aneuploidy

1997 78

workshop on use of T25 in chemical carcinogen evaluation 2001 141

**Subject:****Electronic nicotine, or non-nicotine,  
delivery systems (e-cigarettes),  
potential toxicological risks from****Year Page**

Aerosol particle fraction, characterisation of

2017 28

Carcinogenicity data, overview of available

2018 50

Exposure to EN(N)DS aerosols, metals and solvents, silicon/silicate  
particles, nicotine toxicity

2018 28

Exposure to EN(N)DS aerosols - known constituents and potential  
adverse health outcomes arising from

2020 9

Flavouring compounds, framework for risk assessment of

2019 18

Genotoxic risk, potential

2018 43

Nicotine salts in, a summary of data published to date

2020 34

Statement on,

2020 6

|                                |      |    |
|--------------------------------|------|----|
| Toxicological risks, potential | 2019 | 52 |
|--------------------------------|------|----|

|                              |      |    |
|------------------------------|------|----|
| Addendum to the statement on | 2021 | 26 |
|------------------------------|------|----|

**Subject:**

|                                       |             |             |
|---------------------------------------|-------------|-------------|
| <b>Endocrine disrupting chemicals</b> | <b>Year</b> | <b>Page</b> |
|---------------------------------------|-------------|-------------|

|                                    |      |    |
|------------------------------------|------|----|
| Definition for regulatory purposes | 2010 | 11 |
|------------------------------------|------|----|

|                    |      |    |
|--------------------|------|----|
| Risk assessment of | 2019 | 17 |
|--------------------|------|----|

**Subject:**

|                   |             |             |
|-------------------|-------------|-------------|
| <b>Endosulfan</b> | <b>Year</b> | <b>Page</b> |
|-------------------|-------------|-------------|

|                                                                 |      |    |
|-----------------------------------------------------------------|------|----|
| Endosulfan, pentachlorobenzene and chlordane in the infant diet | 2013 | 18 |
|-----------------------------------------------------------------|------|----|

**Subject:**

|                      |             |             |
|----------------------|-------------|-------------|
| <b>Energy drinks</b> | <b>Year</b> | <b>Page</b> |
|----------------------|-------------|-------------|

|                                                             |      |    |
|-------------------------------------------------------------|------|----|
| in the diet of children and adolescents, final statement on | 2019 | 10 |
|-------------------------------------------------------------|------|----|

|                      |      |    |
|----------------------|------|----|
| interim statement on | 2018 | 29 |
|----------------------|------|----|

**Subject:**

|                                           |             |             |
|-------------------------------------------|-------------|-------------|
| <b>Enrofloxacin (veterinary medicine)</b> | <b>Year</b> | <b>Page</b> |
|-------------------------------------------|-------------|-------------|

|                                       |      |    |
|---------------------------------------|------|----|
| carcinogenicity in laboratory rodents | 1993 | 50 |
|---------------------------------------|------|----|

**Subject:**

**Environmental Tobacco Smoke (ETS) and lung cancer**

COC statement on 1997 88

consideration of paper by Enstrom JE and Kabat GC (2003). British Medical Journal volume 326, 1057-1066 2003 191

**Subject:**

**Environmental mutagens**

Significance of environmental mutagenesis 2004 141

**Subjects:**

**Enzymes**

Amano 90 - submission to COT 2000 15

Enzyme submission COT 2001 9

Chymosin - Enzyme submission COT 1999 16

Enzyme submission COT, modified recovery and purification 2000 16

Enzyme submission -derived from GM aspergillus niger var. awamori 2002 10

|                                                                                   |         |
|-----------------------------------------------------------------------------------|---------|
| Enzyme submission –derived from GM Aspergillus niger var. awamori                 | 2003 8  |
| Hemicellulase Enzyme in bread-making                                              | 1999 19 |
| Immobilised lipase from Rhizopus niveus COT consideration of the safety-in-use of | 1994 9  |
| COT consideration of additional data for                                          | 1998 13 |
| Lipase D Enzyme submission COT                                                    | 2000 16 |
| Enzyme submission COT                                                             | 2001 9  |
| Newlase analytical method to detect rhizoxin                                      | 2000 17 |
| Enzyme submission COT update, method review                                       | 2002 11 |
| Enzyme submission COT,                                                            | 2004 10 |
| Enzyme Submission – Newlase analytical method to detect rhizoxin                  | 2004 10 |
| Xylanase preparation from Aspergillus niger                                       | 2001 13 |
| Microbial enzyme preparations (safety assessment of)                              | 1991 17 |

**Subject:**

**Eosinophilia-myalgia syndrome,  
tryptophan and**

**Year Page**

|                                                                            |      |           |
|----------------------------------------------------------------------------|------|-----------|
| risk to health of tryptophan, particularly in food supplements.            | 2003 | 21,<br>83 |
| COT review of a contaminant in the tryptophan produced by one manufacturer | 2004 | 12        |

**Subject:**

**Epigenetics in carcinogenesis**

**Year Page**

|                              |      |    |
|------------------------------|------|----|
| COC evaluation of            | 2013 | 53 |
| COC evaluation of            | 2016 | 35 |
| in chemical risk assessment, | 2017 | 54 |
| in chemical risk assessment, | 2017 | 43 |
| joint committee workshop on  | 2018 | 42 |

**Subject:**

**Epoxidised soya bean oil**

**Year Page**

|                                                      |      |    |
|------------------------------------------------------|------|----|
| COT evaluation of; TDI                               | 1994 | 8  |
| COT evaluation of; updated guidance from 1994 report | 1999 | 16 |

**Subject:**

**Erythritol**

**Year Page**

laxation 2003 9

sensitivity of young children to polyols 2004 9

**Subject:**

**Erythrosine** Year Page

COT review of 1991 29

**Subject:**

**Ethaboxam** Year Page

partial COM review of 2007 131

**Subject:**

**Ethanol (see also alcohol)** Year Page

acetaldehyde and alcoholic beverages 2000 62

effects on pregnancy, reproduction and infant  
development 1995 8

**Subject:**

**Exhaust, diesel** Year Page

Carcinogenicity of 1991 47

**Subject:****Exposure Assessment****Year Page**

Food chemicals, to

2002 12

Less than lifetime

2020 31

Statement on assessment of less than lifetime exposure

2021 19

single or short term, to carcinogens

2005 140

Draft EFSA Scientific Committee Opinion on scientific criteria for  
grouping chemicals into assessment groups for human risk  
assessment of combined exposure to multiple chemicals

2021 26